Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes

Seminars in Hematology

Volumn 39, Issue 1, 2002, Pages 57-62

  Giralt, Sergio ^a   Anagnostopoulos, Athanasios ^a   Shahjahan, Munir ^a   Champlin, Richard ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ALLOGRAFT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0036141454     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2002.30909     Document Type: Article

References (59)

1. Soluble receptors and other substances that regulate proinflammatory cytokines in young and aging humans
2. Drug therapy: The treatment of multiple myeloma
3. Transfusion associated graft versus host disease
4. Treatment of non Hodgkins lymphoma
5. Bone marrow transplantation
6. Low dose radiation and allogeneic lymphocyte infusions induce complete remissions in refractory cancer patients
7. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s
8. Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: A retrospective analysis of the European Bone Marrow Transplant Group
9. Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft versus malignancy effect
10. The myelodysplastic syndromes: Current approaches to therapy
11. Older patient age remains a risk factor for transplant related mortality (TRM) following nonmyeloablative allogeneic stem cell transplantation
12. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
13. The biology and treatment of acute lymphoblastic leukemia in adults
14. Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients: An update
15. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 65 years of age
16. Hodgkin's disease
17. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia
18. Distint categories of immunologic changes in frail elderly
19. Identical-twin bone marrow (syngeneic) transplantation for hematologic cancers
20. Graft versus host disease
21. The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for AML 1CR is significantly worse after 35 years. Implication for reducing the intensity of the conditioning regimen. Report of the Acute Leukemia Working Party of EBMT
22. Risk factors for acute graft versus host disease
23. How does bone marrow transplantation cure leukemia?
24. Identical twin bone marrow transplantation for leukemia
25. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft versus-leukemia without myeloablative therapy
26. Purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
27. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion
28. Cancer statistics 2001
29. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation
30. Treatment of GVHD-TNF-antibodies and related antagonists
31. Graft-versus leukemia reactions after bone marrow transplantation
32. Transplant registries: Guiding clinical decisions and improving outcomes
33. Chronic myelogenous leukemia: A concise update
34. Transplant lite: Induction of graft vs malignancy using fludarabine based nonablative chemotherapy and allogeneic progenitor-cell transplantation as treatment for lymphoid malignancies
35. Graft-versus-leukemia effect of donor lymphocyte infusions in marrow grafted patients
36. Clinical and laboratory studies of 2-chlorodeoxyadenosine + cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults
37. Acute myeloid leukemia
38. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects
39. Allogeneic stem cell transplantation (SCT) in MDS: Interim results of outcome following nonmyeloablative conditioning compared to standard preparative regimens
40. Metabolism and action of purine nucleoside analogs
41. Graft versus tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies
42. Non-myeloablative stem cell transplant (NMSCT) in AML, ALL, and MDS: Disappointing outcome for patients with advanced phase disease
43. Outcome after allogeneic bone marrow transplant for leukemia in older adults
44. Chronic lymphocytic leukemia
45. Non myeloablative conditioning for HLA-identical related allografts for hematologic malignancies
46. The systemic administration of intravenous melphalan
47. Allogeneic transplantation with non-myeloablative or reduced intensity conditioning: The intensity of the conditioning regimen is related to outcome in patients with active disease but not in those in remission at the time of transplantation
48. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases
49. Transient mixed hematopoietic chimerism in dogs given thymic irradiation before and pharmacologic immunosuppression after marrow transplantation
50. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation
51. Stable mixed hematopoietic chimerism in dog leukocyte antigen identical littermate dogs given lymph node irradiation before and pharmacological immunosuppression after marrow transplantation
52. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms
53. The role of bone marrow transplantation for eradication of malignant disease
54. Bone marrow transplantation for malignant disease
55. Conditioning regimens for marrow grafting
56. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts
57. Antileukemic effect of chronic graft-versus host disease: Contribution to improved survival after allogeneic marrow transplantation
58. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice
59. Cancer immunotherapy with HLA-compatible thoracic duct lymphocyte transplantation. A preliminary report